Wegovy demonstrated significant and sustained weight loss in two-year study in adults with obesity – Novo Nordisk
Results from the STEP 5 phase IIIb trial, presented by Novo Nordisk at the Obesity Week 2021 interactive congress, showed that adults treated with Wegovy (semaglutide 2.4 mg injection) achieved significant and sustained weight loss over the two-year study period . The STEP 5 trial investigated Wegovy vs. placebo, both used with a reduced calorie meal plan and increased physical […]
Recent Comments